SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Celldex Therapeutics, Inc.

Biotech SG&A Efficiency: Bio-Techne vs. Celldex

__timestampBio-Techne CorporationCelldex Therapeutics, Inc.
Wednesday, January 1, 20146071600020622000
Thursday, January 1, 201511940100033837000
Friday, January 1, 201614087900035979000
Sunday, January 1, 201719924300025003000
Monday, January 1, 201824063600019269000
Tuesday, January 1, 201926435900015426000
Wednesday, January 1, 202026058300014456000
Friday, January 1, 202132495100020488000
Saturday, January 1, 202237276600027195000
Sunday, January 1, 202337837800030914000
Monday, January 1, 2024396826000
Loading chart...

Cracking the code

SG&A Efficiency in Biotech: A Comparative Analysis

In the dynamic world of biotechnology, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial for evaluating company performance. Over the past decade, Bio-Techne Corporation has demonstrated a robust growth trajectory in SG&A expenses, increasing by over 550% from 2014 to 2023. This reflects their strategic investments in expanding operations and market reach. In contrast, Celldex Therapeutics, Inc. has shown a more conservative approach, with a modest 50% increase in SG&A expenses over the same period. This disparity highlights differing strategic priorities, with Bio-Techne focusing on aggressive expansion, while Celldex maintains a leaner operational model. Notably, data for Celldex in 2024 is unavailable, suggesting potential shifts in reporting or operational strategy. This analysis underscores the importance of SG&A efficiency as a key indicator of a biotech company's strategic direction and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025